Pharm Res (2011) 28:417–419
DOI 10.1007/s11095-010-0355-8

AAPS Connection

American Association of Pharmaceutical Scientists February 2011

AAPS Launches New LinkedIn Subgroup!

AAPS has launched a new LinkedIn Subgroup, AAPS Careers, to focus discussion on careers in the pharmaceutical sciences within the AAPS LinkedIn community. The new site will also support the AAPS Online Career Center.

While the AAPS Online Career Center remains the most comprehensive resource for hiring companies who wish to recruit highly qualified candidates in the pharmaceutical sciences community, the new LinkedIn Subgroup, AAPS Careers, will help streamline communication with members and make it easier for them to

- ► share knowledge on recent hiring practices
- ► learn through experiences from their peers
- ► find crucial information on the current job market.

Please join the new LinkedIn Subgroup, AAPS Careers, today!

The 46th Annual Pharmaceutical Technologies Arden Conference: Pharmaceutical Development of Biologics: Fundamentals, Challenges, and Recent Advances

March 6–10, 2011
The Thayer Hotel
West Point, NY, USA

Goals and Objectives

This program is designed to provide a comprehensive review of biologic drug development, commonly encountered issues, challenges, and recent advances in bioprocess, formulation, delivery, and manufacturing technologies. Detailed presentations will cover four development areas: biological drug substance and preformulation; formulation, delivery and process development; analytical technologies and PAT; and regulatory landscape and biosimilars. Each topic will include lectures from experts in the field followed by interactive group discussions and case studies in which the audience is strongly encouraged to participate. Attendees are also encouraged to bring practical examples of issues and problems encountered at work for discussion and thought exchange, including success stories as well as lessons learned.

For more information, please visit
www.aapspharmaceutica.com/ardenconference.

AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside

March 14–16, 2011
Bethesda North Marriott & Conference Center
Bethesda, MD, USA

Background

The area of drug transport continues to evolve rapidly, with advances in understanding the role of transport in drug absorption, distribution and excretion, as well as toxicity and disease; improvements in clinical translation of in vitro and preclinical transport studies; and increased regulatory expectations for understanding transport interactions (2010 EMA drug interaction draft guidance and 2010 ITC whitepaper). For the past decade, the AAPS Workshop on Drug Transporters has been the only recurring North American meeting dedicated to discussion of advances in this field, and has a consistent record of relevance to

pharmaceutical scientists. The 2011 workshop will continue to provide a venue for focused interactions with drug transport experts and thought leaders.

Objectives

The recognition of the influence of membrane transporters on drug disposition has driven a surge in drug transport-related research within the pharmaceutical sciences. Although considerable progress has been made over the past 15 years, the field of drug transport continues to evolve, particularly with respect to clinical translation of in vitro/preclinical data (2010 EMA drug interaction draft guidance and 2010 ITC whitepaper), understanding systemic/tissue exposure implications, toxicity/disease pathogenesis, targeting transport for drug delivery, and interplay with metabolism. This fifth biennial AAPS Workshop on Drug Transporters aims to build on the success of previous meetings and provide a continued opportunity for pharmaceutical, academic and regulatory scientists to exchange ideas about the cutting-edge transporter research.

For more information, please visit
www.aapspharmaceutica.com/drugtrans.

Emerging Oral Delivery Strategies and Technologies to Enable Biopharmaceutical Performance of BCS II, III and IV Molecules

April 14–15, 2011
Sheraton Inner Harbor
Baltimore, MD, USA

Goals and Objectives

For small molecules, approximately 60–70% of NMEs are BCS II and IV, and there is increasing need for drug delivery technologies to enable the development of "drug-like" molecules in a timely and cost-effective manner. Proper biopharmaceutical and ADMET properties along with adequate selectivity and potency minimize subsequent failure risks and increase the chance that the most promising leads are advanced to development candidates. In the case of macromolecules (BCS III), intestinal permeability and metabolism are still the major barriers to overcome, with no commercial product on the market despite significant advancements over the last two decades. Proper selection and evaluation of a suitable drug delivery technology using proper in vitro/in vivo methodologies by considering the physicochemical and biopharmaceutical properties of the molecule/macromolecule is critical to the overall drug discovery and development strategy and success. This feature will be highlighted throughout the workshop and introduced by two keynote talks on new paradigms in drug discovery and development and emerging drug delivery technologies. It will then cover the following three areas: one on general drug development principles and considerations, and two on specific drug delivery technologies and case studies: physicochemical and biopharmaceutical properties and evaluation tools, lipid-based systems and solid dispersions, and prodrugs and nanoparticles.

For more information, please visit
www.aapspharmaceutica.com/oraldelivery.

AAPS Workshop on Delivery and Disposition of Biotherapeutics Across the Blood-Brain Barrier

May 14–15, 2011
Hilton San Francisco Union Square
San Francisco, CA, USA

Goals and Objectives

In recent years, a significant effort has been guided toward the identification of novel therapeutic targets for central nervous system (CNS) disorders. However, these efforts have not translated into robust success in developing biotherapeutic modalities for CNS diseases in the industry drug development pipeline. The primary reason is that the blood-brain barrier (BBB) isolates and protects CNS structures, creating a unique biochemically and immunologically privileged environment. Therefore, passage of macromolecules across this barrier is fraught with challenges. Further, even if 0.1 to 0.2% of any biotherapeutic drug modality crosses the BBB, there is no consensus in terms of method to be used or tissue/fluids to be collected for the optimum measurements of the therapeutic. In recent years, some technologies have evolved from academia or the small biotech industry that promise to deliver

biotherapeutics in sufficient quantities. Although successful at the preclinical stage in lower vertebrates, none of these technologies have emerged in the clinical setting. What could be the issues stifling this progress? Investigators in academia as well as in industry have realized that there is a definite lack of proper communication channel that has prevented progress in the development of introduction of biotherapeutics across the BBB. Can we fix this?

For more information, please visit **www.aapspharmaceutica.com/Biotherapeutics.**

Upcoming AAPS Meetings

Log onto **www.aapspharmaceutica.com/meetings** for details.

▶ March 6-10, 2011
The 46th Annual Pharmaceutical Technologies Arden Conference: Pharmaceutical Development of Biologics: Fundamentals, Challenges, and Recent Advances
The Thayer Hotel, West Point, NY, USA

▶ March 14-16, 2011
AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside
Bethesda N. Marriott & Conference Center, Bethesda, MD, USA

▶ April 14-15, 2011
AAPS Workshop on Emerging Oral Delivery Strategies and Technologies to Enable Biopharmaceutical Performance of BCS II, III and IV Molecules
Sheraton Inner Harbor Hotel, Baltimore, MD, USA

▶ May 14-15, 2011
AAPS Workshop on Delivery and Disposition of Biotherapeutics across the Blood Brain Barrier
Hilton San Francisco Union Square, San Francisco, CA, USA

▶ May 16-18, 2011
2011 AAPS National Biotechnology Conference
Hilton San Francisco Union Square, San Francisco, CA, USA

▶ October 23-27, 2011
2011 AAPS Annual Meeting and Exposition
Washington Convention Center
Washington, D.C., USA

aaps®